When compared to standard chemotherapy, the reversible ATP-competitive first-generation EGFR inhibitors, erlotinib and gefitinib, prolonged progression-free survival (PFS) and overall survival of patients with NSCLC who harbor mutant forms of EGFR [37,38,39]. Here, EGFR is linked to non-small cell lung carcinoma.